Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer
| Autor: | Michael Rink, Ronald Simon, Niclas C Blessin, Martina Kluth, Linnea Lindhorst, Roland Dahlem, Till Krech, Till S. Clauditz, Guido Sauter, Wolfgang Höppner, Till Eichenauer, Henrik Zecha, Margit Fisch, Franziska Büscheck, Katharina Möller, Stefan Steurer, Cord Matthies, Christoph Fraune, Claudia Hube-Magg, Ousman Doh, Maximilian Lennartz, Silke Riechardt, Andreas H. Marx |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Male PD-L1 Immune checkpoint therapy Urology Chromophobe cell urologic and male genital diseases B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Immune system Renal cell carcinoma Germany Biomarkers Tumor Medicine Humans Carcinoma Renal Cell Immune Checkpoint Inhibitors Aged Aged 80 and over Tissue microarray biology business.industry Cancer Middle Aged medicine.disease Prognosis Immune checkpoint Kidney Neoplasms 030104 developmental biology Nephrology 030220 oncology & carcinogenesis biology.protein Cancer research UROLOGY - Original Paper Female Neoplasm Grading business Clear cell |
| Zdroj: | International Urology and Nephrology |
| ISSN: | 1573-2584 |
| Popis: | Background PD-L1 expression predicts response to immune checkpoint inhibitors in renal cell carcinomas (RCC), but has also been suggested to be linked to poor patient outcome. Methods We analyzed PD-L1 in > 1400 RCC in a tissue microarray format by immunohistochemistry. Results were compared with histological tumor type, parameters of cancer aggressiveness, and intratumoral CD8+ cytotoxic cells. Result At a cut-off level of 5% PD-L1 positive tumor cells, PD-L1 positivity was seen in 6.3% of 633 clear cell RCC (ccRCC), 18.2% of 165 papillary RCC, 18.8% of 64 chromophobe RCC, and 41.7% of 103 oncocytomas. In ccRCC, PD-L1 positivity was significantly linked to high ISUP (p p p p = 0.0042), short recurrence-free (p p = 0.0002). Intratumoral CD8+ lymphocytes were more frequent in PD-L1 positive (1055 ± 109) than in PD-L1 negative ccRCC (407 ± 28; p + cells (p p p = 0.0027), and Thoenes grade (p p = 0.0280). Conclusions These data suggest that PD-L1 expression in highly immunogenic RCCs facilitates immune evasion and contributes to cancer aggressiveness. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink